Guggenheim initiated coverage on Abivax SA with a new price target
$ABVX
Biotechnology: Pharmaceutical Preparations
Health Care
Guggenheim initiated coverage of Abivax SA with a rating of Buy and set a new price target of $50.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/29/2024 | $48.00 | Buy | Laidlaw |
| 5/20/2024 | $43.00 | Buy | BTIG Research |
| 4/29/2024 | $42.00 | Overweight | Piper Sandler |
| 4/29/2024 | $50.00 | Buy | Guggenheim |
| 11/14/2023 | $15.00 | Equal-Weight | Morgan Stanley |
| 11/14/2023 | $20.00 | Outperform | Leerink Partners |
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax PARIS, France, November 13, 2024, 10:00 pm CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Mark Stenhouse as Board Observer and Advisor to Abivax. Mr. Stenhouse brings more than 30 years of experience in the biopharma industry. Most recently, he served as Chief Operating Officer of Prometheus Biosciences, a biotechn
Abivax Provides Operational and Key Program Update Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1 2025Top-line results from the ABTECT 8-week induction trial expected early Q2 2025, with 44-week maintenance data on pace to read out in Q1 2026; timing assumptions for New Drug Application (NDA) submission remain unchangedContinued progress on pre-clinical combination therapy programSylvie Grégoire named Chair of Abivax's Board of Directors; Dr. Fabio Cataldi named Chief Medical Officer and Dr. David Zhang named Chief Strategy OfficerCash position allows for runway into Q4 2025 through ABTECT 8-
PARIS, France, June 4, 2024 – Abivax SA ((Euronext Paris &, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, held its ordinary and extraordinary general meeting of shareholders on May 30, 2024 (the "General Meeting"), which was chaired by Mr. Marc de Garidel, CEO and Chairman of the Board of Directors of Abivax ("Board"). The shareholders have adopted all the resolutions proposed by the Board and, in particular, the financial statements for the 2023 financial year, the compensation poli
Laidlaw initiated coverage of Abivax SA with a rating of Buy and set a new price target of $48.00
BTIG Research initiated coverage of Abivax SA with a rating of Buy and set a new price target of $43.00
Piper Sandler initiated coverage of Abivax SA with a rating of Overweight and set a new price target of $42.00
SC 13G/A - Abivax S.A. (0001956827) (Subject)
SC 13G - Abivax S.A. (0001956827) (Subject)
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq PARIS, France, November 19, 2024 – 10:30PM CET – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, today announced the implementation of an At-The-Market program ("ATM Program") allowing the Company to issue and sell, including with unsolicited investors who have expressed an interest, ordinary shares in the form of American Depositary Shares ("ADS"), each ADS representing one ordinary share, nominal value €0.01 per share
Abivax presents third quarter 2024 key financial information PARIS, France, November 14, 2024, 10:00 p.m. CET – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today its key financial information for the quarter ended September 30, 2024. Abivax provided the following updates on its business and operational goals in press releases published: On July 15, 2024 press release titled "Abivax provides operational and key program update"On August 6, 2024 press rele
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax PARIS, France, November 13, 2024, 10:00 pm CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Mark Stenhouse as Board Observer and Advisor to Abivax. Mr. Stenhouse brings more than 30 years of experience in the biopharma industry. Most recently, he served as Chief Operating Officer of Prometheus Biosciences, a biotechn
6-K - Abivax S.A. (0001956827) (Filer)
F-3 - Abivax S.A. (0001956827) (Filer)
6-K - Abivax S.A. (0001956827) (Filer)
Abivax Provides Operational and Key Program UpdatePhase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1 2025Top-line results from the ABTECT 8-week induction trial expected early Q2 2025, with 44-week maintenance data on pace to read out in Q1 2026; timing assumptions for New Drug Application (NDA) submission remain unchangedContinued progress on pre-clinical combination therapy programSylvie Grégoire named Chair of Abivax's Board of Directors; Dr. Fabio Cataldi named Chief Medical Officer and Dr. David Zhang named Chief Strategy OfficerCash position allows for runway into Q4 2025 through ABTECT 8-week
U.S. stock futures were mixed this morning, with the Dow futures falling around 50 points on Monday. Shares of AMC Networks Inc. (NASDAQ:AMCX) fell sharply in today's pre-market trading after the company announced a private offering of $125 million of convertible senior notes. AMC Networks shares dipped 9.4% to $14.24 in pre-market trading. Here are some big stocks recording losses in today's pre-market trading session. Evotec SE (NYSE:EVO) shares fell 7.7% to $4.20 in pre-market trading. Absci Corporation (NASDAQ:ABSI) declined 5.8% to $3.75 in pre-market trading after declining around 9% on Friday. Humacyte, Inc. (NASDAQ:HUMA) fell 5.7% to $6.65 in pre-market trading.
BTIG analyst Julian Harrison initiates coverage on Abivax (NASDAQ:ABVX) with a Buy rating and announces Price Target of $43.